Northern Trust
RXRX icon

Northern Trust’s Recursion Pharmaceuticals RXRX Stock Holding History

Northern Trust’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.2M Buy
3,968,411
+528,462
+15% +$2.04M ﹤0.01% 1964
2025
Q4 		$14.1M Buy
3,439,949
+102,653
+3% +$508K ﹤0.01% 1899
2025
Q3 		$16.3M Buy
3,337,296
+422,424
+14% +$2.22M ﹤0.01% 1830
2025
Q2 		$14.7M Buy
2,914,872
+519,684
+22% +$2.55M ﹤0.01% 1835
2025
Q1 		$12.7M Buy
2,395,188
+677
+0% +$4.94K ﹤0.01% 1901
2024
Q4 		$16.2M Buy
2,394,511
+371,886
+18% +$2.5M ﹤0.01% 1833
2024
Q3 		$13.3M Buy
2,022,625
+708,015
+54% +$5.08M ﹤0.01% 1895
2024
Q2 		$9.86M Buy
1,314,610
+27,920
+2% +$244K ﹤0.01% 2006
2024
Q1 		$12.8M Sell
1,286,690
-8,897
-0.7% -$99.1K ﹤0.01% 1893
2023
Q4 		$12.8M Sell
1,295,587
-13,345
-1% -$95.2K ﹤0.01% 1904
2023
Q3 		$10M Buy
1,308,932
+56,945
+5% +$568K ﹤0.01% 2002
2023
Q2 		$9.35M Buy
1,251,987
+96,210
+8% +$673K ﹤0.01% 2112
2023
Q1 		$7.71M Sell
1,155,777
-3,926
-0.3% -$31.1K ﹤0.01% 2195
2022
Q4 		$8.94M Buy
1,159,703
+26,005
+2% +$255K ﹤0.01% 2080
2022
Q3 		$12.1M Buy
1,133,698
+152,416
+16% +$1.54M ﹤0.01% 1853
2022
Q2 		$7.99M Buy
981,282
+121,738
+14% +$815K ﹤0.01% 2199
2022
Q1 		$6.15M Sell
859,544
-26,417
-3% -$281K ﹤0.01% 2459
2021
Q4 		$15.2M Buy
885,961
+635,290
+253% +$12M ﹤0.01% 1962
2021
Q3 		$5.77M Buy
250,671
+8,295
+3% +$235K ﹤0.01% 2636
2021
Q2 		$8.85M Buy
+242,376
New +$7.17M ﹤0.01% 2457

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust's RXRX Position: Q1 2026 in Review

Northern Trust increased its Recursion Pharmaceuticals (RXRX) stake by 15% in Q1 2026, buying an estimated $2.04M and bringing the position to 3,968,411 shares worth $12.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

Northern Trust first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $16.3M in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Northern Trust held 3,968,411 shares of Recursion Pharmaceuticals worth $12.2M as of Q1 2026.
  • Northern Trust bought 528,462 Recursion Pharmaceuticals shares in Q1 2026, an estimated $2.04M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1964 holding.
  • Northern Trust first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Northern Trust's Recursion Pharmaceuticals position peaked at $16.3M in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.